Vascular endothelial growth factor receptor 1, a therapeutic target in cancer, inflammation and other disorders

Current Medicinal Chemistry

Volumn 16, Issue 22, 2009, Pages 2890-2898

  Wu, Yan ^a   Zhu, Zhenping ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CEDIRANIB; CYCLOPHOSPHAMIDE; FLUOROURACIL; FOLINIC ACID; IMC 18F 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PAZOPANIB; RPI 4610; SORAFENIB; SUNITINIB; TB 403; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BONE MARROW CELL; BREAST CANCER; CANCER INVASION; CARCINOGENESIS; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; EMBRYO DEVELOPMENT; HEMATOPOIESIS; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR IMMUNITY;

ANIMALS; HUMANS; INFLAMMATION; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 70349384814     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788803169     Document Type: Review

References (74)

1. Ferrara, N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell. Physio., 2001, 280, 1358-66.
2. Rahimi, N. VEGFR-1 and VEGFR-2: Two non-identical twins with a unique physiognomy. Frot. Biosci. 2006, 11, 818-29.
3. Fong, G.H.; Rossant, J.; Gertsenstein, M; Breitman, M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature, 1995, 376, 66-70.
4. Hiratsuka, S.; Minowa, O.; Kuno, J.; Noda, T.; Shibuya, M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA, 1998, 95, 9349-54.
5. Fong, G.H.; Klingensmith, J.; Wood, C.R.; Rossant, J.; Breitman, M.L. Regulation of flt-1 expression during mouse embryogenesis suggests a role in the establishment of vascular endothelium. Dev. Dyn., 1996, 207, 1-10.
6. Kearney, J.B.; Kappas, N.C.; Ellerstrom, C.; DiPaola, F.W.; Bautch, V.L. The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. Blood, 2004, 103, 4527-35.
7. Tammela, T.; Enholm, B.; Alitalo, K.; Paavonen, K. The biology of vascular endothelial growth factors Cardiovasc. Res., 2005, 65, 550-563.
8. Adini, A.; Kornaga, T.; Firoozbakht, F.; Benjamin, L.E. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res., 2002, 62, 2749-52.
9. Park, J.E.; Chen, H.H.; Winer, J.; Houck, K.A.; Ferrara, N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem., 1994, 269, 25646-54.
10. Carmeliet, P.; Moons, L.; Luttun, A.; Vincenti, V.; Compernolle, V.; De Mol, M.; Wu, Y.; Bono, F.; Devy, L.; Beck, H.; Scholz, D.; Acker, T.; DiPalma, T.; Dewerchin, M.; Noel, A.; Stalmans, I.; Barra, A.; Blacher, S.; Vandendriessche, T.; Ponten, A.; Eriksson, U.; Plate, K. H.; Foidart, J. M.; Schaper. W.; Charnock-Jones, D. S.; Hicklin, D. J.; Herbert, J. M.; Collen, D.; and Persico, M. G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med., 2001, 7, 575-83.
11. Aase, K.; von Euler, G.; Li, X.; Ponten, A.; Thoren, P.; Cao, R.; Cao, Y.; Olofsson, B.; Gebre-Medhin, S.; Pekny, M.; Alitalo, K.; Betsholtz, C.; Eriksson, U. Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation, 2001, 104, 358-64.
12. Gunningham, S.P.; Currie, M.J.; Han, C.; Robinson, B.A.; Scott, P.A.; Harris, A.L.; Fox, S.B. VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. J. Pathol., 2001, 193, 325-32.
13. Kawakami, M.; Furuhata, T.; Kimura, Y.; Yamaguchi, K.; Hata, F.; Sasaki, K.; Hirata, K. Expression analysis of vascular endothelial growth factors and their relationships to lymph node metastasis in human colorectal cancer. J. Exp. Clin. Cancer Res., 2003, 2, 229-37.
14. Wierzbowska, A.; Robak, T.; Wrzesień-Kuś, A.; Krawczyńska, A.; Lech-Marańda, E.; Urbańska-Ryś, H. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur. Cytokine Netw. 2003, 14, 149-53.
15. Bando, H.; Weich, H.A.; Brokelmann, M.; Horiguchi, S.; Funata, N.; Ogawa, T.; Toi, M. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br. J. Cancer, 2005, 92, 553-61.
16. Robak, E.; Sysa-Jedrzejewska, A.; Robak, T. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus. Mediat. Inflamm., 2003, 12, 293-8.
17. Hiratsuka, S.; Maru, Y.; Okada, A.; Seiki, M.; Noda, T.; Shibuya, M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res., 2001, 61, 1207-13.
18. Marchand, G.S.; Noiseux, N.; Tanguay, J.F.; Sirois, M.G. Blockade of in vivo VEGF-mediated angiogenesis by antisense gene therapy: role of Flk-1 and Flt-1 receptors. Am. J. Physiol. Heart Circ. Physiol., 2002, 282, H194-204.
19. Bates, R.C.; Goldsmith, J.D.; Bachelder, R.E.; Brown, C.; Shibuya, M.; Oettgen, P.; Mercurio, A.M. Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Curr. Biol., 2003, 13, 1721-7.
20. Yang, A.D.; Camp, E.R.; Fan, F.; Shen, L.; Gray, M.J.; Liu, W.; Somcio, R.; Bauer, T.W.; Wu, Y.; Hicklin, D.J.; Ellis, L.M. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res., 2006, 66, 46-51.
21. Murakami, M.; Zheng, Y.; Hirashima, M.; Suda, T.; Morita, Y.; Ooehara, J.; Ema, H.; Fong, G.H.; Shibuya, M. VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 658-64.
22. Kusmartsev, S.; Eruslanov, E.; Kübler, H.; Tseng, T.; Sakai, Y.; Su, Z.; Kaliberov, S.; Heiser, A.; Rosser, C.; Dahm, P.; Siemann, D.; Vieweg, J. Oxidative stress regulates expression of VEGFR1 in myeloid cells: Link to tumor-induced immune suppression in renal cell carcinoma. J. Immunol., 2008, 181, 346-53.
23. Clauss, M.; Weich, H.; Breier, G.; Knies, U.; Rockl, W.; Waltenberger, J.; Risau, W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities: Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J. Biol. Chem., 1996, 271, 17629-34.
24. Sawano, A.; Iwai, S.; Sakurai, Y.; Ito, M.; Shitara, K.; Nakahata, T.; Shibuya, M. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood, 2001, 97, 785-91.
25. Lemstrom, K.B.; Krebs, R.; Nykanen, A.I.; Tikkanen, J.M.; Sihvola, R.K.; Aaltola, E.M.; Hayry, P.J.; Wood, J.; Alitalo, K.; Yla-Herttuala, S.; Koskinen, P.K. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation, 2002, 105, 2524-30.
26. Bottomley, M.J.; Webb, N.J.; Watson, C.J.; Holt, L.; Bukhari, M.; Denton, J.; Freemont, A.J.; Brenchley, P.E. Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clin. Exp. Immunol., 2000, 119, 182-8.
27. Luttun, A.; Tjwa, M.; Moons, L.; Wu, Y; Angelillo-Scherrer, A.; Liao, F.; Nagy, J.A.; Hooper, A.; Priller, J.; De Klerck, B.; Compernolle, V.; Daci, E.; Bohlen, P.; Dewerchin, M.; Herbert, J.M.; Fava, R.; Matthys, P.; Carmeliet, G.; Collen, D.; Dvorak, H.F.; Hicklin, D.J.; Carmeliet, P. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med., 2002, 8, 831-40.
28. Hattori, K.; Heissig, B.; Wu, Y.; Dias, S.; Tejada, R.; Ferris, B.; Hicklin, D.J.; Zhu, Zh.; Bohlen, P.; Witte, L.; Hendrikx, J.; Hackett, N.R.; Crystal, R.G.; Moore, M.A.S.; Werb, Z.; Lyden, D.; Rafii, S. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow micro-environment. Nat. Med. 2002, 8, 841-9.
29. Decaussin, M.; Sartelet, H.; Robert, C.; Moro, D.; Claraz, C.; Brambilla, C.; Brambilla, E. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): Correlation with angiogenesis and survival. J. Pathol., 1999, 188, 369-77.
30. Lacal, P.M.; Failla, C.M.; Pagani, E.; Odorisio, T.; Schietroma, C.; Falcinelli, S.; Zambruno, G.; D'Atri, S. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J. Invest. Dermatol., 2000, 115, 1000-7
31. Price, D.J.; Miralem, T.; Jiang, S.; Steinberg, R.; Avraham, H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ., 2001, 12, 129-35.
32. Wang, E.S.; Teruya-Feldstein, J.; Wu, Y.; Zhu, Z.; Hicklin, D.J.; Moore, M.A.S. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood, 2004, 104, 2893-902.
33. Fan, F.; Wey, J.S.; McCarty, M.F.; Belcheva, A.; Liu, W.; Bauer, T.W.; Somcio, R.; Wu, Y.; Hooper, A.; Hicklin, D.J.; Ellis, L.M. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene. 2005, 24, 2647-53.
34. Wey, J.S.; Fan, F.; Gray, M.J.; Bauer, T.W.; McCarty, M.F.; Somcio, R.; Liu, W.; Evans, D.B.; Hicklin, D.J.; Ellis, L.M. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer, 2005, 104, 427-38
35. Wu, Y.; Hooper, A.T.; Zhong, Z.; Witte, L; Bohlen, P.; Rafii, S.; Hicklin, D.J. The Vascular Endothelial Growth Factor Receptor (VEGFR-1) Supports Growth and Survival of Human Breast Carcinoma. Int. J. Cancer, 2006, 119, 1519-29.
36. Lalla, R.V.; Boisoneau, D.S.; Spiro, J.D.; Kreutzer, D.L. Expression of vascular endothelial growth factor receptors on tumor cells in head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg., 2003, 129, 882-8.
37. Ferrer, F.A.; Miller, L.J.; Lindquist, R.; Kowalczyk, P.; Laudone, V.P.; Albertsen, P.C.; Kreutzer, D.L. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology, 1999, 54, 567-72
38. Fragoso, R.; Pereira, T.; Wu, Y.; Zhu, Z.; Cabecadas, J.; Dias, S. VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood, 2006, 107, 1608-16.
39. Podar K.; Anderson K.C. The pathophysiologic role of VEGF in hematologic malignancies: Therapeutic implications. Blood, 2005, 105, 1383-95.
40. Meunier-Carpentier, S.; Dales, J.P.; Djemli, A.; Garcia, S.; Bonnier, P.; Andrac-Meyer, L.; Lavaut, M.N.; Allasia, C.; Charpin, C. Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. Int. J. Oncol. 2005, 26, 977-84.
41. Toi, M.; Bando, H.; Ogawa, T.; Muta, M.; Hornig, C.; Weich, H. A. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int. J. Cancer, 2001, 98, 14-8.
42. Lyden, D.; Hattori, K.; Dias, S.; Costa, C.; Blaikie, P.; Butros, L.; Chadburn, A.; Heissig, B.; Marks, W.; Witte, L.; Wu, Y.; Hicklin, D.; Zhu, Z.; Hackett, N.R.; Crystal, R.G.; Moore, M.A.S.; Hajjar, K. A.; Manova, K.; Benezra, R.; Rafii, S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med., 2001, 7, 1194-201.
43. + haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature, 2005, 438, 820-7.
44. Vincent, L.; Jin, D.K.; Karajannis, M.A.; Shido, K.; Hooper, A.T.; Rashbaum, W.K.; Pytowski, B.; Wu, Y.; Hicklin, D.J.; Zhu, Z.; Bohlen, P.; Niesvizky, R.; Rafii, S. Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factora/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells. Cancer Res., 2005, 65, 3185-92.
45. Selvaraj, S.K.; Giri, R.K.; Perelman, N.; Johnson, C.; Malik, P.; Kalra, V. K. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood, 2003, 102, 1515-24.
46. Murakami, M.; Iwai, S.; Hiratsuka, S.; Yamauchi, M.; Nakamura, K.; Iwakura, Y.; Shibuya, M. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood, 2006, 108, 1849-56.
47. Shibuya, M. Vascular endothelial growth factor receptor-1 (VEGFR-1/ Flt-1): A dual regulator for angiogenesis. Angiogenesis, 2006, 9, 225-30.
48. Krause, D. S.; Theise, N. D.; Collector, M. I.; Henegariu, O.; Hwang, S.; Gardner, R.; Neutzel, S.; Sharkis, S.J. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell, 2001, 105, 369-377.
49. Ziegler, B.L.; Valtieri, M.; Porada, G.A.; De Maria, R.; Muller, R.; Masella, B.; Gabbianelli, M.; Casella, I.; Pelosi, E.; Bock, T.; Zanjani, E.D.; Peschle, C. KDR receptor: A key marker defining hematopoietic stem cells. Science, 1999, 285, 1553-8.
50. Peichev, M.; Naiyer, A.J.; Pereira, D.; Zhu, Z.; Lane, W.J.; Williams, M.; Oz, M.C.; Hicklin, D.J.; Witte, L.; Moore, M.A.S.; Rafii, S. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood, 2000, 95, 952-8.
51. Haruta, H.; Nagata, Y.; Todokoro, K. Role of Flk-1 in mouse hematopoietic stem cells. FEBS Lett., 2001, 507, 45-8.
52. Rafii, S.; Heissig, B.; Hattori, K. Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Therapy, 2002, 9, 631-41.
53. Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev., 2004, 25, 581-611.
54. Gille, J.; Heidenreich, R.; Pinter, A.; Schmitz, J.; Boehme, B.; Hicklin, D.J.; Henschler, R.; Breier, G. Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation. Int. J. Cancer, 2007, 120, 1899-908.
55. Dikov M.M.; Ohm J.E.; Ray N.; Tchekneva E.E.; Burlison J.; Moghanaki, D.; Nadaf, S.; Carbone, D.P. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J. Immunol., 2005, 174, 215-22.
56. Laxmanan, S. Robertson, S.W.; Wang, E.; Lau, J.S.; Briscoe, D.M.; Mukhopadhyay, D. Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. Biochem. Biophys. Res. Commun., 2005, 334, 193-8.
57. Lin, Y.L.; Liang, Y.C.; Chiang, B.L. Placental growth factor down-regulates type 1 T helper immune response by modulating the function of dendritic cells. J. Leukoc. Biol., 2007, 82, 1473-80.
58. Raisky, O.; Nykänen, A.I.; Krebs, R.; Hollmen, M.; Keränen, M.A.; Tikkanen, J.M.; Sihvola, R.; Alhonen, L.; Salven, P.; Wu, Y.; Hicklin, D.J.; Alitalo, K.; Koskinen, P.K.; Lemström, K.B. VEGFR-1 and -2 regulate inflammation, myocardial angiogenesis, and arteriosclerosis in chronically rejecting cardiac allografts. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 819-25
59. Autiero, M.; Luttun, A.; Tjwa, M.; Carmeliet, P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: Novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J. Thrombosis Haemost., 2003, 1, 1356-70.
60. Lutgens, E.; Cleutjens, K.B.; Heeneman, S.; Koteliansky, V.E.; Burkly, L.C.; Daemen, M. J. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc. Natl. Acad. Sci. USA, 2000, 97, 7464-9.
61. Wu, Y.; Zhong, Z.; Huber, J.; Bassi, R.; Finnerty, B.; Corcoran, E.; Li, H.; Navarro, E.; Balderes, P.; Jimenez, X.; Koo, H.; Mangalampalli, V.R.; Ludwig, D.L.; Tonra, J.R.; Hicklin, D.J. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin. Cancer Res., 2006, 12, 6573-84.
62. Pavco, P.A.; Bouhana, K.S.; Gallegos, A.M.; Agrawal, A.; Blanchard, K.S.; Grimm, S.L.; Jensen, K.L.; Andrews, L.E.; Wincott, F.E.; Pitot, P.A.; Tressler, R.J.; Cushman, C.; Reynolds, M.A.; Parry, T.J. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin. Cancer Res., 2000, 6, 2094-103.
63. Podar, K.; Catley, L.; Tai, Y.T.; Shringarpure, R.; Carvalho, P.; Hayashi, T.; Burger, R.; Schlossman, R.L.; Richardson, P.G.; Pandite, L.N.; Kumar, R.; Hideshima, T.; Chauhan, D.; Anderson, K.C. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood, 2004, 103, 3474-9.
64. Morabito, A.; De Maio, E.; Di Maio, M.; Normanno, N.; Perrone, F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions. Oncologist, 2006, 11, 753-64.
65. Bae, D.G.; Kim, T.D.; Li, G.; Yoon, W.H.; Chae, C.B. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis. Clin. Cancer Res., 2005, 11, 2651-61.
66. Taylor, A. P.; Goldenberg, D. M. Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts. Molecular. Cancer Therap., 2007, 6, 524-531.
67. Ishizaki, H.; Tsunoda, T.; Wada, S.; Yamauchi, M.; Shibuya, M.; Tahara, H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin. Cancer Res., 2006, 12, 5841- 9.
68. Fischer, C.; Jonckx, B.; Mazzone, M.; Zacchigna, S.; Loges, S.; Pattarini, L.; Chorianopoulos, E.; Liesenborghs, L.; Koch, M.; De Mol, M.; Autiero, M.; Wyns, S.; Plaisance, S.; Moons, L.; van Rooijen, N.; Giacca, M.; Stassen, J.M.; Dewerchin, M.; Collen, D.; Carmeliet, P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007, 131, 463-75.
69. Hiratsuka, S.; Nakamura, K.; Iwai, S.; Murakami, M.; Itoh, T.; Kijima, H.; Shipley, J.M.; Senior, R.M.; Shibuya, M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell, 2002, 2, 289-300.
70. Rowinsky, E.K. The erbB Family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Ann. Rev. Med. 2004, 55, 433-57.
71. Weiner, L.M.; Carter, P. The rollercoaster ride to anti-cancer antibodies. Nat. Biotech., 2003, 21, 510-1.
72. Clynes, R.A.; Towers, T.L.; Presta, L.G.; Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med., 2000, 6, 443-6.
73. Cohen, D.J.; Hochster, H.S. Rationale for combining biotherapy in the treatment of advanced colon cancer. Gastrointest. Cancer Res., 2008, 2, 145-51.
74. Bianco, R.; Damiano, V.; Gelardi, T.; Daniele, G.; Ciardiello, F.; Tortora, G. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. Curr. Pharm. Des., 2007, 13, 3358-67.